CPHI שווי כולל של נכסי החברה China Pharma

The timeline of stock price changes helps illustrate the strategy of China Pharma Holdings (CPHI) to ensure supply independence through its own plant in Hainan. Total assets amount to 29.39, supported by high capacity utilization in psychotropic drug production facilities and the upgrading of GMP-compliant equipment. The business relies on the expansion of its generic drug portfolio and growing demand for antibiotics in China's regional clinics.

The financial stability assessment of China Pharma Holdings (CPHI) is based on an analysis of total assets—the sum of equity and liabilities—reverse-calculated via ROA to determine resource efficiency. The trend in controlled resources reflects the company's expansion rate, which is critical for protecting margins against pricing pressure and dumping in the neurological generics market by expanding distribution.